Synonyms for anthera or Related words with anthera

actavis              astellas              actelion              indevus              valeant              abbvie              santhera              apotex              synta              xanodyne              aegerion              sepracor              biomarin              bionumerik              esperion              cipla              ranbaxy              patheon              savient              debiopharm              vioquest              sunesis              predix              trius              phynova              orexigen              pharmacosmetics              encysive              sicor              lundbeck              celltrion              mylan              servier              alnylam              axys              scios              aptalis              pherin              amphastar              eisai              ignyta              tekmira              newron              syndax              pharmascience              glaxowellcome              nexmed              inflazyme              incimmunogen              jagsonpal             

Examples of "anthera"
Cerace anthera is a species of moth of the family Tortricidae. It is found in China.
In March 2012, Anthera halted further investigation of varespladib per a recommendation from an independent Data Safety Monitoring Board.
Anthera Pharmaceuticals acquired varespladib sodium from Lilly and Shionogi in 2006. In 2007, the U.S. Food and Drug Administration (FDA) granted varespladib sodium orphan drug status for its potential to treat patients with sickle-cell disease. In 2009, Anthera Pharmaceuticals completed a Phase II study of varespladib sodium in subjects with sickle cell disease at risk for ACS.
"Poranthera" is native to Australia and New Zealand. The name is derived from the Greek word, "poros", "opening or pore", and the Latin word "anthera", "anther".
Stenanthera is a genus of flowering plants in the heath or heather family Ericaceae. The name of the genus comes from Greek words, "stenos" = narrow and "anthera" = anthers.
Blisibimod, a fusion protein inhibitor of BAFF, is in development by Anthera Pharmaceuticals, also primarily for the treatment of systemic lupus erythematosus.
Varespladib methyl was originally developed jointly by Eli Lilly and Company and Shionogi & Co., Ltd., and was acquired by Anthera Pharmaceuticals in 2006.
Varespladib methyl (also known as A-002, formerly LY333013 and S-3013) is a secretory phospholipase A2 (sPLA2) inhibitor formerly under development by Anthera Pharmaceuticals as a treatment for acute coronary syndrome (ACS). Varespladib methyl is an orally bioavailable prodrug of the molecule varespladib. From 2006 to 2012, varespladib methyl was under active investigation by Anthera Pharmaceuticals as a potential therapy for several inflammatory diseases, including acute coronary syndrome.
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. A-623 (Blisibimod) is Anthera’s leading drug candidate which is being developed for IgA nephropathy.
The name "Elythranthera" is derived from the Ancient Greek word "elytron" meaning "cover", "sheath" or "husk" and the Latin word "anthera" meaning "the pollen-bearing part of a stamen" referring to the column wings.
Varespladib sodium (also known as A-001, previously LY315920 and S-5920) is a sodium salt of varespladib designed for intravenous delivery. It was under evaluation by Anthera Pharmaceuticals as an anti-inflammatory sPLA2 inhibitor for the prevention of acute chest syndrome (ACS), the leading cause of death for patients with sickle-cell disease.
July 2014, Anthera acquired Sollpura (Liprotamase) from Eli Lilly and Company. Sollpura is an investigational pancreatic enzyme replacement therapy (PERT) that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.
Blisibimod (also known as A-623, formerly AMG 623) is a selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS), being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. It is currently under active investigation in clinical trials.
Varespladib is an inhibitor of the IIa, V, and X isoforms of secretory phospholipase A2 (sPLA2). The molecule acts as an anti-inflammatory agent by disrupting the first step of the arachidonic acid pathway of inflammation. From 2006 to 2012, varespladib was under active investigation by Anthera Pharmaceuticals as a potential therapy for several inflammatory diseases, including acute coronary syndrome and acute chest syndrome. The trial was halted in March 2012 due to inadequate efficacy.
Blisibimod was initially developed by Amgen, with Phase I trials demonstrating comparable safety between the blisibimod and placebo treatments. It was subsequently acquired by Anthera Pharmaceuticals, who in 2010 initiated a global Phase II study called PEARL-SC to investigate the efficacy, safety, and tolerability of blisibimod in subjects with systemic lupus erythematosus. The PEARL-SC study, completed in April 2012, yielded data that has been published. Blisibimod is currently being tested in a Phase 3 study, CHABLIS-SC1, for systemic lupus erythematosus, and a Phase 2 study, BRIGHT-SC, for IgA nephropathy.
In 2008, Westphal worked with Aldrich and Alexey Margolin to found Alnara Pharmaceuticals, which was created to develop ways to formulate biopharmaceuticals so they could be taken by mouth, instead of by injection. Margolin had been CEO of Altus Therapeutics, which had been developing liprotamase, which it had licensed from the Cystic Fibrosis Foundation, but ran out of money. Alnara acquired the license and focused its resources on further developing liprotamase; Eli Lilly and Company acquired Alnara in July 2010 on the promise of that data acquired by Alnara. Lilly submitted a new drug application to the FDA in 2011, which the FDA rejected, finding no clear benefit over existing products and requiring an additional clinical trial. Lilly took a $122.6 million write-down on the value of the asset, and then sold it to Anthera Pharmaceuticals in 2014.